MX9708528A - Quimiosina bata-13 humana. - Google Patents

Quimiosina bata-13 humana.

Info

Publication number
MX9708528A
MX9708528A MX9708528A MX9708528A MX9708528A MX 9708528 A MX9708528 A MX 9708528A MX 9708528 A MX9708528 A MX 9708528A MX 9708528 A MX9708528 A MX 9708528A MX 9708528 A MX9708528 A MX 9708528A
Authority
MX
Mexico
Prior art keywords
disclosed
polypeptides
chemokine polypeptides
detecting
chemokine
Prior art date
Application number
MX9708528A
Other languages
English (en)
Other versions
MXPA97008528A (es
Inventor
Haodong Li
George Seibel
Original Assignee
Human Genome Sciences Inc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Smithkline Beecham Corp filed Critical Human Genome Sciences Inc
Publication of MXPA97008528A publication Critical patent/MXPA97008528A/es
Publication of MX9708528A publication Critical patent/MX9708528A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Se describen polipéptidos de quimiosina humana y ADN que codifica para tales polipéptidos de quimiosina, y un procedimiento para producir tales polipéptidos por técnicas recombinantes. También se describen métodos pare utilizar tales polipéptidos de quimiosina para el tratamiento de leucemia, tumores fibroticos, sanado de heridas y psoriasis. También se describen antagonistas contra tales polipéptidos de quimiosina y su uso como una sustancia terapéutica para tratar artritis reumatoide, enfermedades autoimunes y enfermedades inflamatorias e infecciosas cronicas y aguadas, reacciones alérgicas, fiebre independiente de prostaglandina y fallo de médula osea. También se describen ensayos de diagnostico para detectar enfermedades relacionadas con mutaciones en las secuencias deácido nucleico y concentraciones alteradas de los polipéptidos. También se describen ensayos de diagnostico para detectar mutaciones en los polinucleotidos que codifican para los polipéptidos de quimiosina y para detectar concentraciones alteradas del polipéptido en un huésped.
MX9708528A 1995-06-06 1995-06-06 Quimiosina bata-13 humana. MX9708528A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCPCT/US1995/007294 1995-06-06
PCT/US1995/007294 WO1996039521A1 (en) 1995-06-06 1995-06-06 Human chemokine beta-13

Publications (2)

Publication Number Publication Date
MXPA97008528A MXPA97008528A (es) 1998-02-01
MX9708528A true MX9708528A (es) 1998-02-28

Family

ID=22249282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708528A MX9708528A (es) 1995-06-06 1995-06-06 Quimiosina bata-13 humana.

Country Status (10)

Country Link
EP (1) EP0832233B1 (es)
KR (1) KR19990008322A (es)
AT (1) ATE278780T1 (es)
AU (1) AU713267B2 (es)
DE (1) DE69533627T2 (es)
DK (1) DK0832233T3 (es)
ES (1) ES2227553T3 (es)
MX (1) MX9708528A (es)
PT (1) PT832233E (es)
WO (1) WO1996039521A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
WO1998011226A2 (en) * 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
AU7625598A (en) * 1996-12-03 1998-06-29 Amgen, Inc. Novel protein with chemokine activity
WO1998024908A1 (en) * 1996-12-05 1998-06-11 Human Genome Sciences, Inc. Human chemokine beta-13
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
US6548631B1 (en) * 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
US6093542A (en) * 1998-01-09 2000-07-25 Akzo Nobel N.V. Isothermal transcription based amplification assay for the detection and quantitation of macrophage derived chemokine RNA
JP2003514517A (ja) * 1999-11-03 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトケモカインβ−１３
CA2484121A1 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
EP2640744A4 (en) 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd NEUTRALIZATION OF ANTIBODIES TO CCL20

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92685A0 (en) * 1988-12-16 1990-09-17 Us Commerce Dna encoding lymphokine/cytokine like proteins,cells transformed thereby and production of said proteins and antibodies against them

Also Published As

Publication number Publication date
WO1996039521A1 (en) 1996-12-12
EP0832233A1 (en) 1998-04-01
ES2227553T3 (es) 2005-04-01
PT832233E (pt) 2004-12-31
KR19990008322A (ko) 1999-01-25
DE69533627T2 (de) 2005-10-13
DE69533627D1 (en) 2004-11-11
AU713267B2 (en) 1999-11-25
EP0832233A4 (en) 1998-07-01
EP0832233B1 (en) 2004-10-06
DK0832233T3 (da) 2005-01-24
ATE278780T1 (de) 2004-10-15
AU2820895A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
MX9708537A (es) Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas.
DE69533627D1 (en) Humanes chemokin beta-13
DE69433648D1 (de) Menschliche chemokin-polypeptide
NZ332318A (en) Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
NZ288799A (en) Human chemokine beta-9 polypeptides, polynucleotides encoding the chemokine and preparation thereof
EP0814158A3 (en) Human C3a receptor variant; uses in diagnostics and therapeutics
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
EP0823478A3 (en) Human cartilege GP 39-like gene
EP0792370A4 (en) INTERLEUKIN-1 CONVERSION ENZYME-TYPE APOPTOSIS PROTEASE-3 AND 4 -g (b)
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP0812913A3 (en) HR-1 receptor, a receptor of the cytokine receptors family
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
MX9709090A (es) Quimiocina beta-11 humana y quimiocina alfa-1 humana.
WO2003031571A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
EP0845535A3 (en) Leader peptidase (lep) from Streptococcus
EP0837136A3 (en) Novel topoisomerase I
EP0835938A3 (en) Topoisomerase I
EP0841399A3 (en) Mammalian fin-1 nucleic acid (a caspase) and protein sequences and uses therefor
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
EP0843011A3 (en) RsbU-1 derived from Staphylococcus
WO2003052061A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003050245A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003004617A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal